Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Oxford Immunotec Global PLC is a diagnostics & research business based in the US. Oxford Immunotec Global shares (OXFD) are listed on the NASDAQ and all prices are listed in US Dollars. Oxford Immunotec Global employs 273 staff and has a trailing 12-month revenue of around USD$57.3 million.
|52-week range||USD$8.37 - USD$23.1081|
|50-day moving average||USD$21.9318|
|200-day moving average||USD$15.9926|
|Wall St. target price||USD$22.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$5.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Oxford Immunotec Global stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oxford Immunotec Global's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oxford Immunotec Global's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Oxford Immunotec Global shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$57.3 million|
|Gross profit TTM||USD$54.4 million|
|Return on assets TTM||-4.99%|
|Return on equity TTM||-8.19%|
|Market capitalisation||USD$561.9 million|
TTM: trailing 12 months
There are currently 136,459 Oxford Immunotec Global shares held short by investors – that's known as Oxford Immunotec Global's "short interest". This figure is 11.1% down from 153,441 last month.
There are a few different ways that this level of interest in shorting Oxford Immunotec Global shares can be evaluated.
Oxford Immunotec Global's "short interest ratio" (SIR) is the quantity of Oxford Immunotec Global shares currently shorted divided by the average quantity of Oxford Immunotec Global shares traded daily (recently around 974707.14285714). Oxford Immunotec Global's SIR currently stands at 0.14. In other words for every 100,000 Oxford Immunotec Global shares traded daily on the market, roughly 140 shares are currently held short.
However Oxford Immunotec Global's short interest can also be evaluated against the total number of Oxford Immunotec Global shares, or, against the total number of tradable Oxford Immunotec Global shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oxford Immunotec Global's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Oxford Immunotec Global shares in existence, roughly 10 shares are currently held short) or 0.0077% of the tradable shares (for every 100,000 tradable Oxford Immunotec Global shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oxford Immunotec Global.
Find out more about how you can short Oxford Immunotec Global stock.
We're not expecting Oxford Immunotec Global to pay a dividend over the next 12 months.
Over the last 12 months, Oxford Immunotec Global's shares have ranged in value from as little as $8.37 up to $23.1081. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oxford Immunotec Global's is 1.3831. This would suggest that Oxford Immunotec Global's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.